Table 3.

Univariate survival analysis of baseline characteristics for OS and PFS.

Variable	OS		PFS		Variable	OS		PFS
	HR	P	HR	P		HR	P	HR	P
Age					Adrenal
<65	1.00				No	1.00
≥ 65	0.88	0.43	0.92	0.59	Yes	1.36	0.31	1.69	0.05
Gender					Liver
Male	1.00				No	1.00
Female	1.08	0.60	1.05	0.74	Yes	1.20	0.41	1.22	0.34
Smoking Status					Others
Never	1.00				No	1.00
Current or ever	0.84	0.25	0.97	0.80	Yes	0.83	0.49	0.70	1.17
Drinking Status					Radiotherapy
Never	1.00				No	1.00
Current or ever	0.97	0.86	1.19	0.26	Yes	1.36	0.04	1.48	0.005
Location					Chemotherapy
Left	1.00				No chemotherapy	1.00
Right	1.25	0.13	1.17	0.27	First-line treatment	0.62	0.04	0.82	0.22
Family history of cancer					Second-line treatment	1.28	0.54	1.78	0.13
No	1.00				Anti-VEGF
Yes	0.93	0.69	1.00	0.98	No	1.00
Histology					Yes	1.11	0.72	1.27	0.37
Adenocarcinoma	1.00				EGFR-TKI
SCC	1.09	0.63	0.87	0.43	No	1.00
Others	1.18	0.42	1.00	0.99	Yes	1.20	0.24	1.37	0.03
Local or distant metastases					Chemotherapy regimen
M1a	1.00				Platin-Vinorelbine
M1b	1.83	0.01	2.05	0.001	No	1.00
M1c	2.20	<0.001	2.76	<0.001	Yes	0.74	0.07	0.92	0.58
Metastatic site					Platin-Gemcitabine
Lung contralateral					No	1.00
No	1.00				Yes	0.99	0.93	1.10	0.52
Yes	1.23	0.37	1.19	0.78	Platin-Pemetrexed
Pleural					No	1.00
No	1.00				Yes	0.95	0.76	1.06	0.69
Yes	1.31	0.07	1.21	0.17	Others
Cerebral					No	1.00
No	1.00				Yes	0.72	0.08	0.72	0.08
Yes	1.76	<0.001	1.91	<0.001
Bones
No	1.00
Yes	1.38	0.03	1.55	0.001